Considering your experience with Sharlife so far, how likely are you to recommend us to a friend or colleague?
Not at all likelyExtremely likely
(Optional)
Shanghai Henlius Biotech, Inc. Class H
2696Health technology
$4.6B
Market Cap
Shariah Analysis
Failed
Business
Cash
Liabilities
Based on AAOIFI screening standards, Shanghai Henlius Biotech, Inc. Class H appears to be Failed.
Business Activity
Revenue breakdown data currently unavailable.
Financial Screening
FYE 2024
Cash (<30%)6.55%
Non-Shariah Cash Items
Cash And Cash Equivalents$773M
Liabilities (<30%)30.93%
Non-Shariah Liabilities
Current Capital Lease Obligation$65M
Long Term Debt$951.3M
Long Term Capital Lease Obligation$137.4M
Current Debt$2.5B
Market Data
Exchange
HKEX
CurrencyUSD
CountryHong Kong
Last Updated2025-12-15
Disclaimer: Shariah screening is based on the latest available financial data. Market conditions and company activities may change. Always conduct your own due diligence.
HKEX
